ReviewSensors (Basel, Switzerland)2026
Gold- or Silver-Nanoparticle SERS Platforms for Plasma-Based Diagnostics and AI-Driven Analysis.
Review in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Surface-enhanced Raman spectroscopy (SERS) has emerged as a highly promising analytical technique for disease diagnostics due to its exceptional sensitivity, molecular specificity, and ability to detect a broad range of biomarkers in complex biological matrices. This review provides a comprehensive overview of gold- and silver-nanoparticle-based SERS platforms for plasma disease diagnostics, covering advances in plasmonic nanostructures, biological sample analysis, biomarker detection, and AI-driven spectral data processing. Particular emphasis is placed on the application of SERS to clinically relevant biofluids, especially plasma, where the technique has demonstrated considerable potential for detecting diseases such as cancer, inflammatory disorders, and neurological conditions. The review also critically examines the major challenges currently limiting the clinical translation of SERS technologies. These include variability associated with substrate fabrication, matrix-induced signal fluctuations, limited interlaboratory reproducibility, and the lack of standardized protocols for spectral preprocessing and data analysis. Strategies proposed to address these issues are discussed, including comprehensive post-synthesis substrate characterization, optimization of biological sample preparation, advanced spectral preprocessing workflows, and the integration of machine learning and artificial intelligence algorithms to improve diagnostic robustness and reproducibility. Collectively, the advances summarized in this review indicate that SERS-based diagnostic technologies are rapidly progressing beyond proof-of-concept studies toward clinically applicable systems. Continued interdisciplinary collaboration and standardization efforts will be essential to bridge the remaining gap between experimental SERS methodologies and routine clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.